Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of subcutaneous human plasma-derived C1-esterase inhibitor for prophylaxis in hereditary angioedema
2014-001054-42Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of c1-esterase inhibitor in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (2 arms), sponsored by CSL Limited. Primary endpoint: Person-time incidence rates of specified safety events. Started Oct 2014; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2014-001054-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001054-42.